

Platelet activation and platelet-monocyte aggregate formation and expression in patients with severe COVID-19

Blood

136, 1330-1341

DOI: [10.1182/blood.2020007252](https://doi.org/10.1182/blood.2020007252)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Platelets Promote Thromboinflammation in SARS-CoV-2 Pneumonia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2975-2989.	2.4	144
2	The Immune Nature of Platelets Revisited. Transfusion Medicine Reviews, 2020, 34, 209-220.	2.0	104
3	Vascular Manifestations of COVID-19 – Thromboembolism and Microvascular Dysfunction. Frontiers in Cardiovascular Medicine, 2020, 7, 598400.	2.4	65
4	Megakaryocytes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2812-2814.	2.4	1
5	Over time relationship between platelet reactivity, myocardial injury and mortality in patients with SARS-CoV-2-associated respiratory failure. Platelets, 2021, 32, 560-567.	2.3	31
6	Non-Alloimmune Mechanisms of Thrombocytopenia and Refractoriness to Platelet Transfusion. Transfusion Medicine Reviews, 2020, 34, 242-249.	2.0	11
7	Anakinra: a silver lining in COVID-19?. Critical Care, 2020, 24, 598.	5.8	3
8	Coronavirus 2019, Microthromboses, and Platelet Activating Factor. Clinical Therapeutics, 2020, 42, 1850-1852.	2.5	26
9	SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. Journal of Hematology and Oncology, 2020, 13, 120.	17.0	505
10	Platelets Can Associate With SARS-CoV-2 RNA and Are Hyperactivated in COVID-19. Circulation Research, 2020, 127, 1404-1418.	4.5	394
11	Perspectives on Platelet Heterogeneity and Host Immune Response in Coronavirus Disease 2019 (COVID-19). Seminars in Thrombosis and Hemostasis, 2020, 46, 826-830.	2.7	19
12	COVID-19 concerns aggregate around platelets. Blood, 2020, 136, 1221-1223.	1.4	20
13	Coagulation abnormalities in SARS-CoV-2 infection: overexpression tissue factor. Thrombosis Journal, 2020, 18, 38.	2.1	45
14	Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses. MBio, 2020, 11, .	4.1	92
15	<scp>COVID</scp>–19, microthromboses, inflammation, and platelet activating factor. BioFactors, 2020, 46, 927-933.	5.4	50
16	Revisiting One of the Dreaded Outcomes of the Current Pandemic: Pulmonary Embolism in COVID-19. Medicina (Lithuania), 2020, 56, 670.	2.0	2
17	Immune Mechanisms in Cardiovascular Diseases Associated With Viral Infection. Frontiers in Immunology, 2020, 11, 570681.	4.8	29
18	Hyperthrombotic Milieu in COVID-19 Patients. Cells, 2020, 9, 2392.	4.1	27

#	ARTICLE	IF	CITATIONS
19	Severe COVID-19: A multifaceted viral vasculopathy syndrome. <i>Annals of Diagnostic Pathology</i> , 2021, 50, 151645.	1.3	76
20	Rotational thromboelastometry results are associated with care level in COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 437-445.	2.1	38
21	The Impact of COVID-19 Disease on Platelets and Coagulation. <i>Pathobiology</i> , 2021, 88, 15-27.	3.8	331
22	Platelet activation contributes to hypoxia-induced inflammation. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L413-L421.	2.9	21
23	Association of Neutrophil Activation, More Than Platelet Activation, With Thrombotic Complications in Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2021, 223, 933-944.	4.0	113
24	SARS-CoV-2-associated coagulopathy and thromboembolism prophylaxis in children: A single-center observational study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 522-530.	3.8	50
25	The role of NO in COVID-19 and potential therapeutic strategies. <i>Free Radical Biology and Medicine</i> , 2021, 163, 153-162.	2.9	82
26	Search for SARS-CoV-2 RNA in platelets from COVID-19 patients. <i>Platelets</i> , 2021, 32, 284-287.	2.3	28
27	Coronavirus Disease 2019-associated Coagulopathy. <i>Mayo Clinic Proceedings</i> , 2021, 96, 203-217.	3.0	84
28	Is there a role for the ACE2 receptor in SARS-CoV-2 interactions with platelets?. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 46-50.	3.8	75
29	Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets. <i>Physiological Reviews</i> , 2021, 101, 545-567.	28.8	78
30	A scoping review of the pathophysiology of COVID-19. <i>International Journal of Immunopathology and Pharmacology</i> , 2021, 35, 205873842110480.	2.1	42
31	The Central Role of Fibrinolytic Response in COVID-19—A Hematologist's Perspective. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1283.	4.1	38
32	Platelet reactivity to thrombin differs between patients with COVID-19 and those with ARDS unrelated to COVID-19. <i>Blood Advances</i> , 2021, 5, 635-639.	5.2	52
33	ICU Admission Levels of Endothelial Biomarkers as Predictors of Mortality in Critically Ill COVID-19 Patients. <i>Cells</i> , 2021, 10, 186.	4.1	81
34	COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. <i>Thorax</i> , 2021, 76, 412-420.	5.6	239
36	COVID-19: Integrating the Complexity of Systemic and Pulmonary Immunopathology to Identify Biomarkers for Different Outcomes. <i>Frontiers in Immunology</i> , 2020, 11, 599736.	4.8	16
37	Thrombosis, an Important Piece in the COVID-19 Puzzle – From Pathophysiology to Therapy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
38	Unprovoked serotonin syndrome-like presentation of SARS-CoV-2 infection: A small case series. SAGE Open Medical Case Reports, 2021, 9, 2050313X2110320.	0.3	5
39	Impairment in selenocysteine synthesis as a candidate mechanism of inducible coagulopathy in COVID-19 patients. Medical Hypotheses, 2021, 147, 110475.	1.5	8
40	Platelets and viruses. Platelets, 2021, 32, 325-330.	2.3	21
41	Therapeutic Potential of Resveratrol in COVID-19-Associated Hemostatic Disorders. Molecules, 2021, 26, 856.	3.8	49
42	Severe SARS-CoV-2 Infection Inhibits Fibrinolysis Leading to Changes in Viscoelastic Properties of Blood Clot: A Descriptive Study of Fibrinolysis in COVID-19. Thrombosis and Haemostasis, 2021, 121, 1417-1426.	3.4	32
43	Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider. RMD Open, 2021, 7, e001549.	3.8	14
44	Thrombocytopathies: Not Just Aggregation Defects—The Clinical Relevance of Procoagulant Platelets. Journal of Clinical Medicine, 2021, 10, 894.	2.4	15
45	Platelet Lysate Nebulization Protocol for the Treatment of COVID-19 and Its Sequels: Proof of Concept and Scientific Rationale. International Journal of Molecular Sciences, 2021, 22, 1856.	4.1	7
46	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. Annals of the Rheumatic Diseases, 2021, 80, 698-706.	0.9	37
47	Thrombocytopenia in Virus Infections. Journal of Clinical Medicine, 2021, 10, 877.	2.4	60
48	The COVID-19 pandemics and the relevance of biosafety facilities for metagenomics surveillance, structured disease prevention and control. Biosafety and Health, 2021, 3, 1-3.	2.7	13
49	COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies. British Journal of Haematology, 2021, 193, 43-51.	2.5	49
51	Platelet hyperactivity in COVID-19: Can the tomato extract Fruitflow® be used as an antiplatelet regime?. Medical Hypotheses, 2021, 147, 110480.	1.5	8
52	Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis. American Journal of Hematology, 2021, 96, 471-479.	4.1	129
53	Platelet Fcγ3RIIA in immunity and thrombosis: Adaptive immunothrombosis. Journal of Thrombosis and Haemostasis, 2021, 19, 1149-1160.	3.8	21
54	Don't Do Anything! Just Stand There!. Chest, 2021, 159, 908-909.	0.8	1
55	Post-acute COVID-19 syndrome. Nature Medicine, 2021, 27, 601-615.	30.7	3,051
56	Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer. Clinical Cancer Research, 2021, 27, 2706-2711.	7.0	2

#	ARTICLE	IF	CITATIONS
57	Immune responses to SARS-CoV-2 infection in Humans and ACE2 humanized mice. <i>Fundamental Research</i> , 2021, 1, 124-130.	3.3	5
58	COVID-19 is Associated with an Acquired Factor XIII Deficiency. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1668-1669.	3.4	15
59	The Weight of Obesity in Immunity from Influenza to COVID-19. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 638852.	3.9	24
60	Impact of COVID-19 Pandemic on Patients with Immune Thrombocytopaenia. <i>Medicina (Lithuania)</i> , 2021, 57, 219.	2.0	1
61	SARS-CoV-2 Infection: Modulator of Pulmonary Embolism Paradigm. <i>Journal of Clinical Medicine</i> , 2021, 10, 1064.	2.4	8
62	Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target. <i>International Immunopharmacology</i> , 2021, 92, 107336.	3.8	9
63	Phytochemicals as Potential Therapeutics for SARS-CoV-2-Induced Cardiovascular Complications: Thrombosis and Platelet Perspective. <i>Frontiers in Pharmacology</i> , 2021, 12, 658273.	3.5	8
64	In Silico Evaluation of Cyclophilin Inhibitors as Potential Treatment for SARS-CoV-2. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab189.	0.9	5
65	Aspirin Resistance in Obese and Elderly Patients with COVID-19?. <i>American Journal of Medicine</i> , 2021, 134, e297.	1.5	1
66	Aging versus youth: Endocrine aspects of vulnerability for COVID-19. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, , 1.	5.7	6
67	SARS-CoV-2 interacts with platelets and megakaryocytes via ACE2-independent mechanism. <i>Journal of Hematology and Oncology</i> , 2021, 14, 72.	17.0	62
68	Animal Models of COVID-19 II. Comparative Immunology. <i>ILAR Journal</i> , 2021, 62, 17-34.	1.8	20
69	Identifying clinical and biochemical phenotypes in acute respiratory distress syndrome secondary to coronavirus disease-2019. <i>EClinicalMedicine</i> , 2021, 34, 100829.	7.1	28
70	Thrombotic Events in COVID-19 Are Associated With a Lower Use of Prophylactic Anticoagulation Before Hospitalization and Followed by Decreases in Platelet Reactivity. <i>Frontiers in Medicine</i> , 2021, 8, 650129.	2.6	9
71	The role of co-infections and secondary infections in patients with COVID-19. <i>Pneumonia (Nathan Qld) Tj ETQq0 0 0 rgBT /Overlock 10 T</i>	6.15	190
73	Platelet Function in Viral Immunity and SARS-CoV-2 Infection. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 419-426.	2.7	14
74	Dissecting lipid metabolism alterations in SARS-CoV-2. <i>Progress in Lipid Research</i> , 2021, 82, 101092.	11.6	71
75	Platelets in COVID-19: â€œinnocent by-standersâ€ or active participants?. <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2021, 20, 184-191.	0.3	4

#	ARTICLE	IF	CITATIONS
76	Single-cell multi-omics analysis of the immune response in COVID-19. <i>Nature Medicine</i> , 2021, 27, 904-916.	30.7	452
77	Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 319-329.	22.7	594
78	GABAA-Receptor Agonists Limit Pneumonitis and Death in Murine Coronavirus-Infected Mice. <i>Viruses</i> , 2021, 13, 966.	3.3	21
81	Patients with COVID-19: in the dark-NETs of neutrophils. <i>Cell Death and Differentiation</i> , 2021, 28, 3125-3139.	11.2	189
82	Distinct phenotypes of platelet, monocyte, and neutrophil activation occur during the acute and convalescent phase of COVID-19. <i>Platelets</i> , 2021, 32, 1092-1102.	2.3	13
83	Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases. <i>Experimental Hematology and Oncology</i> , 2021, 10, 34.	5.0	15
84	Clinical Assessment of Endothelial Function in Convalescent COVID-19 Patients Undergoing Multidisciplinary Pulmonary Rehabilitation. <i>Biomedicines</i> , 2021, 9, 614.	3.2	27
86	Clinical features and prognostic factors in Covid-19: A prospective cohort study. <i>EBioMedicine</i> , 2021, 67, 103378.	6.1	79
87	Defective NET clearance contributes to sustained FXII activation in COVID-19-associated pulmonary thrombo-inflammation. <i>EBioMedicine</i> , 2021, 67, 103382.	6.1	61
89	Interplay between inflammation and thrombosis in cardiovascular pathology. <i>Nature Reviews Cardiology</i> , 2021, 18, 666-682.	13.7	337
90	Lessons learnt from COVID-19 coagulopathy. <i>EJHaem</i> , 2021, 2, 577-584.	1.0	12
91	COVID-19-related coagulopathy: A review of pathophysiology and pharmaceutical management. <i>Cell Biology International</i> , 2021, 45, 1832-1850.	3.0	27
92	Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19. <i>Vascular Medicine</i> , 2021, 26, 626-632.	1.5	26
94	Secondary analysis of transcriptomes of SARS-CoV-2 infection models to characterize COVID-19. <i>Patterns</i> , 2021, 2, 100247.	5.9	4
95	Cerebral venous thrombosis in COVID-19. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 1039-1045.	3.6	38
96	International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 992-998.	2.1	10
97	High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients. <i>FASEB Journal</i> , 2021, 35, e21666.	0.5	95
98	SARS-CoV-2 and Plasma Hypercoagulability. <i>Cellular and Molecular Bioengineering</i> , 2021, 14, 513-522.	2.1	11

#	ARTICLE	IF	CITATIONS
99	Thromboplasmin inflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies. <i>Frontiers in Immunology</i> , 2021, 12, 649122.	4.8	34
100	Immunothrombosis in Acute Respiratory Dysfunction of COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 651545.	4.8	17
101	Pathological Features of Enterovirus 71-Associated Brain and Lung Damage in Mice Based on Quantitative Proteomic Analysis. <i>Frontiers in Microbiology</i> , 2021, 12, 663019.	3.5	9
102	Point of care diagnostic of hypercoagulability and platelet function in COVID-19 induced acute respiratory distress syndrome: a retrospective observational study. <i>Thrombosis Journal</i> , 2021, 19, 39.	2.1	11
103	Increased platelet activation in SARS-CoV-2 infected non-hospitalised children and adults, and their household contacts. <i>British Journal of Haematology</i> , 2021, 195, 90-94.	2.5	13
104	Platelet Activation and Plasma Levels of Furin Are Associated With Prognosis of Patients With Coronary Artery Disease and COVID-19. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2080-2096.	2.4	21
105	Thrombosis in Covid-19 and non-Covid-19 pneumonia: role of platelets. <i>Platelets</i> , 2021, 32, 1009-1017.	2.3	12
107	Innate immune response analysis in COVID-19 and kawasaki disease reveals MIS-C predictors. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 623-632.	1.7	13
108	Inflammation, Infection and Venous Thromboembolism. <i>Circulation Research</i> , 2021, 128, 2017-2036.	4.5	94
109	Pneumatosis Intestinalis in the Setting of COVID-19: A Single Center Case Series From New York. <i>Frontiers in Medicine</i> , 2021, 8, 638075.	2.6	5
110	THE PROTHROMBOTIC STATE ASSOCIATED WITH SARS-COV-2 INFECTION: PATHOPHYSIOLOGICAL ASPECTS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021045.	1.3	16
111	Dietary Antiplatelets: A New Perspective on the Health Benefits of the Water-Soluble Tomato Concentrate Fruitflow®. <i>Nutrients</i> , 2021, 13, 2184.	4.1	11
112	SARS-CoV-2 infection induces the activation of tissue factor-mediated coagulation via activation of acid sphingomyelinase. <i>Blood</i> , 2021, 138, 344-349.	1.4	35
113	Platelet-leukocyte interactions in the pathogenesis of viral infections. <i>Platelets</i> , 2022, 33, 200-207.	2.3	18
114	Immunothrombosis: a COVID-19 concerto. <i>British Journal of Haematology</i> , 2021, 194, 491-493.	2.5	2
116	Tissue factor upregulation is associated with SARS-CoV-2 in the lungs of COVID-19 patients. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2268-2274.	3.8	32
117	Low-dose aspirin for early COVID-19: does the early bird catch the worm?. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 785-788.	4.1	13
118	Platelet activation in critically ill COVID-19 patients. <i>Annals of Intensive Care</i> , 2021, 11, 113.	4.6	61

#	ARTICLE	IF	CITATIONS
119	Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multicenter, open-label, randomized controlled trial. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2225-2234.	3.8	103
120	Heparin prevents in vitro glycocalyx shedding induced by plasma from COVID-19 patients. <i>Life Sciences</i> , 2021, 276, 119376.	4.3	44
121	Mechanisms of immunothrombosis in COVID-19. <i>Current Opinion in Hematology</i> , 2021, 28, 445-453.	2.5	30
122	The emerging association between COVID-19 and acute stroke. <i>Trends in Neurosciences</i> , 2021, 44, 527-537.	8.6	30
123	Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia following ChAdOx1 nCoV-19 vaccine in a pregnant woman. <i>Haematologica</i> , 2021, 106, 3025-3028.	3.5	10
124	Pathophysiology of COVID-19-associated acute kidney injury. <i>Nature Reviews Nephrology</i> , 2021, 17, 751-764.	9.6	280
125	Platelet Innate Immune Receptors and TLRs: A Double-Edged Sword. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7894.	4.1	38
126	The Role of P-Selectin in COVID-19 Coagulopathy: An Updated Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7942.	4.1	20
127	Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets. <i>Blood</i> , 2021, 138, 1481-1489.	1.4	66
130	Advocacy of targeting protease-activated receptors in severe coronavirus disease 2019. <i>British Journal of Pharmacology</i> , 2022, 179, 2086-2099.	5.4	12
131	The SARS-CoV-2/Receptor Axis in Heart and Blood Vessels: A Crisp Update on COVID-19 Disease with Cardiovascular Complications. <i>Viruses</i> , 2021, 13, 1346.	3.3	11
132	Nebulization with alkaline hypertonic ibuprofen induces a rapid increase in platelets circulating in COVID-19 patients but not in healthy subjects. <i>Platelets</i> , 2021, , 1-8.	2.3	0
133	Impact of COVID-19 on Thrombus Burden and Outcome in Acute Myocardial Infarction. <i>Cureus</i> , 2021, 13, e16817.	0.5	2
134	The Role of Acidosis in the Pathogenesis of Severe Forms of COVID-19. <i>Biology</i> , 2021, 10, 852.	2.8	41
135	Disrupted Resolution Mechanisms Favor Altered Phagocyte Responses in COVID-19. <i>Circulation Research</i> , 2021, 129, e54-e71.	4.5	46
136	Thromboembolic Complications in Severe COVID-19: Current Antithrombotic Strategies and Future Perspectives. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2021, 21, 23-29.	0.7	7
137	Nonsteroidal anti-inflammatory drugs and glucocorticoids in COVID-19. <i>Advances in Biological Regulation</i> , 2021, 81, 100818.	2.3	10
138	Do inflammaging and coagul-aging play a role as conditions contributing to the co-occurrence of the severe hyper-inflammatory state and deadly coagulopathy during COVID-19 in older people?. <i>Experimental Gerontology</i> , 2021, 151, 111423.	2.8	18

#	ARTICLE	IF	CITATIONS
139	Treatment of COVID-19 patients with quercetin: a prospective, single center, randomized, controlled trial. Turkish Journal of Biology, 2021, 45, 518-529.	0.8	21
140	Alterations in platelets during SARS-CoV-2 infection. Platelets, 2022, 33, 192-199.	2.3	14
141	Alterações hematológicas e hemostasia na COVID-19: uma revisão de literatura. Research, Society and Development, 2021, 10, e171101119409.	0.1	1
142	Specific Features of the Coagulopathy Signature in Severe COVID-19 Pneumonia. Frontiers in Medicine, 2021, 8, 675191.	2.6	7
143	Dysregulated Maresin Concentrations in Plasma and Nasal Secretions From Patients With Chronic Rhinosinusitis. Frontiers in Immunology, 2021, 12, 733019.	4.8	5
144	Disseminated intravascular coagulation and its immune mechanisms. Blood, 2022, 139, 1973-1986.	1.4	15
146	COVID-19 Immunobiology: Lessons Learned, New Questions Arise. Frontiers in Immunology, 2021, 12, 719023.	4.8	28
147	P2Y12 receptor blockers are anti-inflammatory drugs inhibiting both circulating monocytes and macrophages including THP-1 cells. Scientific Reports, 2021, 11, 17459.	3.3	14
148	COVID-19 and biomarkers of thrombosis: focus on von Willebrand factor and extracellular vesicles. Journal of Thrombosis and Thrombolysis, 2021, 52, 1010-1019.	2.1	10
149	Coagulation profiles and viscoelastic testing in multisystem inflammatory syndrome in children. Pediatric Blood and Cancer, 2021, 68, e29355.	1.5	9
151	Tissue factor expression, extracellular vesicles, and thrombosis after infection with the respiratory viruses influenza A virus and coronavirus. Journal of Thrombosis and Haemostasis, 2021, 19, 2652-2658.	3.8	29
152	History of COVID-19 infection is not associated with increased d-dimer levels and risk of deep-vein thrombosis in total joint arthroplasty. Archives of Orthopaedic and Trauma Surgery, 2023, 143, 785-789.	2.4	5
153	Vitamin D and Platelets: A Menacing Duo in COVID-19 and Potential Relation to Bone Remodeling. International Journal of Molecular Sciences, 2021, 22, 10010.	4.1	13
154	Platelet GPVI (Glycoprotein VI) and Thrombotic Complications in the Venous System. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2681-2692.	2.4	38
155	Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection. EClinicalMedicine, 2021, 39, 101069.	7.1	48
157	Are Platelets SARS-CoV-2's "Dead End"? Circulation Research, 2021, 129, 647-649.	4.5	2
158	Endothelial Cell Activation by SARS-CoV-2 Spike S1 Protein: A Crosstalk between Endothelium and Innate Immune Cells. Biomedicines, 2021, 9, 1220.	3.2	27
159	Thrombosis, an important piece in the COVID-19 puzzle: From pathophysiology to therapy. , 2021, 25, 601-608.		5

#	ARTICLE	IF	CITATIONS
160	Network-based transcriptomic analysis identifies the genetic effect of COVID-19 to chronic kidney disease patients: A bioinformatics approach. Saudi Journal of Biological Sciences, 2021, 28, 5647-5656.	3.8	12
161	COVID-19 Associated Acute Respiratory Distress Syndrome. Critical Care Clinics, 2021, 37, 777-793.	2.6	6
162	Platelets in the perspective of COVID-19; pathophysiology of thrombocytopenia and its implication as prognostic and therapeutic opportunity. International Immunopharmacology, 2021, 99, 107995.	3.8	27
163	Don't forget arterial thrombosis in patients with COVID-19: A case series. Thrombosis Update, 2021, 5, 100065.	0.9	2
164	Platelets are Hyperactivated but Show Reduced Glycoprotein VI Reactivity in COVID-19 Patients. Thrombosis and Haemostasis, 2021, 121, 1258-1262.	3.4	30
165	Elevated factor V activity and antigen levels in patients with Covid-19 are related to disease severity and 30-day mortality. American Journal of Hematology, 2021, 96, E98-E100.	4.1	6
166	Bothrops lanceolatus snake (Fer-de-lance) venom triggers inflammatory mediators storm in human blood. Archives of Toxicology, 2021, 95, 1129-1138.	4.2	11
167	SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotype. Cell Death and Disease, 2021, 12, 50.	6.3	77
168	Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis, 2021, 24, 505-517.	7.2	105
169	Role of Tissue Factor in the Pathogenesis of COVID-19 and the Possible Ways to Inhibit It. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110039.	1.7	21
170	Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19. Pharmacotherapy, 2020, 40, 1130-1151.	2.6	63
171	Investigation of CD26, a potential SARS-CoV-2 receptor, as a biomarker of age and pathology. Bioscience Reports, 2020, 40, .	2.4	25
172	Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists. Clinical Science, 2020, 134, 2987-3006.	4.3	35
173	A Review of Pathophysiology, Clinical Features, and Management Options of COVID-19 Associated Coagulopathy. Shock, 2021, 55, 700-716.	2.1	31
177	Biodistribution and serologic response in SARS-CoV-2 induced ARDS: A cohort study. PLoS ONE, 2020, 15, e0242917.	2.5	12
179	A review of ischemic stroke in COVID-19: currently known pathophysiological mechanisms. Neurological Sciences, 2022, 43, 67-79.	1.9	16
180	Molecular mechanisms of vasculopathy and coagulopathy in COVID-19. Biological Chemistry, 2021, 402, 1505-1518.	2.5	10
181	Role of SARS-CoV-2 -induced cytokines and growth factors in coagulopathy and thromboembolism. Cytokine and Growth Factor Reviews, 2022, 63, 58-68.	7.2	25

#	ARTICLE	IF	CITATIONS
182	Comprehensive Review of Cardiovascular Complications of Coronavirus Disease 2019 and Beneficial Treatments. <i>Cardiology in Review</i> , 2022, 30, 145-157.	1.4	11
183	Adverse Outcome in Non-Severe COVID-19: Potential Diagnostic Coagulation Tests. <i>Reports</i> , 2021, 4, 35.	0.5	0
184	Platelets and COVID-19. <i>Hamostaseologie</i> , 2021, 41, 379-385.	1.9	47
185	Immune Response in Severe and Non-Severe Coronavirus Disease 2019 (COVID-19) Infection: A Mechanistic Landscape. <i>Frontiers in Immunology</i> , 2021, 12, 738073.	4.8	24
186	COVID-19 Is a Multi-Organ Aggressor: Epigenetic and Clinical Marks. <i>Frontiers in Immunology</i> , 2021, 12, 752380.	4.8	23
187	Mechanisms of Immunothrombosis by SARS-CoV-2. <i>Biomolecules</i> , 2021, 11, 1550.	4.0	11
188	Role of neutrophils, platelets, and extracellular vesicles and their interactions in COVID-19-associated thrombopathy. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 17-31.	3.8	45
189	Inflammatory Mediators of Platelet Activation: Focus on Atherosclerosis and COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11170.	4.1	34
191	Cellular and molecular mechanisms in COVID-19 coagulopathy: role of inflammation and endotheliopathy. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 282-290.	2.1	25
192	State-of-the-art review - A review on snake venom-derived antithrombotics: Potential therapeutics for COVID-19-associated thrombosis?. <i>International Journal of Biological Macromolecules</i> , 2021, 192, 1040-1057.	7.5	9
193	Models for SARS-CoV-2 associated thrombocytopenia associated with hemophagocytic histiocytes. <i>Medical Hypotheses</i> , 2021, 157, 110700.	1.5	1
194	Unconventional CD147-dependent platelet activation elicited by SARS-CoV-2 in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 434-448.	3.8	50
195	Factors associated with a SARS-CoV-2 recurrence after hospital discharge among patients with COVID-19: systematic review and meta-analysis. <i>Journal of Zhejiang University: Science B</i> , 2020, 21, 940-947.	2.8	4
197	Are Aspirin and Apixaban Sufficient to Prevent Immunothrombosis in COVID-19?. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
198	Significance of MPV, RDW and PDW with the Severity and Mortality of COVID-19 and Effects of Acetylsalicylic Acid Use. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110488.	1.7	9
199	Kidney in the net of acute and long-haul coronavirus disease 2019: a potential role for lipid mediators in causing renal injury and fibrosis. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, 31, 36-46.	2.0	11
200	Platelet extracellular vesicles in COVID-19: Potential markers and makers. <i>Journal of Leukocyte Biology</i> , 2021, 111, 63-74.	3.3	26
206	A Review of Platelet-Activating Factor As a Potential Contributor to Morbidity and Mortality Associated with Severe COVID-19. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110517.	1.7	8

#	ARTICLE	IF	CITATIONS
207	COVID-19, the Pandemic of the Century and Its Impact on Cardiovascular Diseases. <i>Cardiology Discovery</i> , 2021, 1, 233-258.	0.5	6
208	Thrombocytopathy vs Platelet hyper-reactivity in COVID-19: diverse pathologies, disease outcomes and therapeutic implications. <i>Platelets</i> , 2021, , 1-6.	2.3	3
209	Metabolic Regulation of Inflammation and Its Resolution: Current Status, Clinical Needs, Challenges, and Opportunities. <i>Journal of Immunology</i> , 2021, 207, 2625-2630.	0.8	2
210	Complexity of immune responses in COVID-19. <i>Seminars in Immunology</i> , 2021, 55, 101545.	5.6	10
211	A peptide from the staphylococcal protein Efb binds Pâ€selectin and inhibits the interaction of platelets with leukocytes. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 729-741.	3.8	5
212	Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis. <i>Frontiers in Immunology</i> , 2021, 12, 779453.	4.8	59
213	Robust thrombolytic and anti-inflammatory action of a constitutively active ADAMTS13 variant in murine stroke models. <i>Blood</i> , 2022, 139, 1575-1587.	1.4	10
214	Caught at the Scene of the Crime: Platelets and Neutrophils Are Conspirators in Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 63-66.	2.4	4
215	Hemostatic System (Fibrinogen Level, D-Dimer, and FDP) in Severe and Non-Severe Patients With COVID-19: A Systematic Review and Meta-Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110109.	1.7	14
216	Upregulation of cAMP prevents antibody-mediated thrombus formation in COVID-19. <i>Blood Advances</i> , 2022, 6, 248-258.	5.2	19
217	Response to comment on â€SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lungâ€™. <i>ELife</i> , 2022, 11, .	6.0	1
219	Mechano-Redox Control of Integrins in Thromboinflammation. <i>Antioxidants and Redox Signaling</i> , 2022, 37, 1072-1093.	5.4	1
220	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. <i>Nature Reviews Cardiology</i> , 2022, 19, 475-495.	13.7	180
221	Plateletâ€Leucocyte Aggregates as Novel Biomarkers in Cardiovascular Diseases. <i>Biology</i> , 2022, 11, 224.	2.8	11
222	The ongoing enigma of SARSâ€CoVâ€2 and platelet interaction. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12642.	2.3	11
223	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Nonâ€Critically Ill Hospitalized Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 227.	7.4	89
224	Monoclonal antibodies as a trick or treat for COVIDâ€19? The example of abcximab. <i>Journal of Medical Virology</i> , 2022, 94, 1794-1795.	5.0	1
225	Janus Kinase Signaling Pathway and Its Role in COVID-19 Inflammatory, Vascular, and Thrombotic Manifestations. <i>Cells</i> , 2022, 11, 306.	4.1	15

#	ARTICLE	IF	CITATIONS
226	Vasculopathy in COVID-19. <i>Blood</i> , 2022, 140, 222-235.	1.4	63
227	Pathophysiology of Cardiac Injury in COVID-19 Patients with Acute Ischaemic Stroke: What Do We Know So Far? A Review of the Current Literature. <i>Life</i> , 2022, 12, 75.	2.4	6
228	Evaluation of admission levels of P, E and L selectins as predictors for thrombosis in hospitalized COVID-19 patients. <i>Clinical and Experimental Medicine</i> , 2022, 22, 567-575.	3.6	22
229	Platelets and Antiplatelet Medication in COVID-19-Related Thrombotic Complications. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 802566.	2.4	7
230	Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 13-28.	3.4	5
231	COVID-19 and Panax ginseng: Targeting platelet aggregation, thrombosis and the coagulation pathway. <i>Journal of Ginseng Research</i> , 2022, 46, 175-182.	5.7	8
232	Platelet and Megakaryocyte Roles in Innate and Adaptive Immunity. <i>Circulation Research</i> , 2022, 130, 288-308.	4.5	47
233	Longitudinal Trend of Plasma Concentrations of Extracellular Vesicles in Patients Hospitalized for COVID-19. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 770463.	3.7	27
234	Purinergic signaling elements are correlated with coagulation players in peripheral blood and leukocyte samples from COVID-19 patients. <i>Journal of Molecular Medicine</i> , 2022, 100, 569-584.	3.9	12
235	Platelets modulate CD4 ⁺ T cell function in COVID-19 through a PD-L1 dependent mechanism. <i>British Journal of Haematology</i> , 2022, 197, 283-292.	2.5	5
236	Inflammation-Induced Coagulopathy Substantially Differs Between COVID-19 and Septic Shock: A Prospective Observational Study. <i>Frontiers in Medicine</i> , 2021, 8, 780750.	2.6	9
237	Pathological sequelae of long-haul COVID. <i>Nature Immunology</i> , 2022, 23, 194-202.	14.5	408
238	Longitudinal multiparametric characterization of platelet dysfunction in COVID-19: Effects of disease severity, anticoagulation therapy and inflammatory status. <i>Thrombosis Research</i> , 2022, 211, 27-37.	1.7	12
239	Pathological effects of SARS-CoV-2 on hematological and immunological cells: Alterations in count, morphology, and function. <i>Pathology Research and Practice</i> , 2022, 231, 153782.	2.3	16
240	Resolving sticky relationships between platelets and lymphocytes in COVID-19: A role for checkpoint inhibitors?. <i>British Journal of Haematology</i> , 2022, 197, 247-249.	2.5	1
241	Transcriptional landscape of circulating platelets from patients with COVID-19 reveals key subnetworks and regulators underlying SARS-CoV-2 infection: implications for immunothrombosis. <i>Cell and Bioscience</i> , 2022, 12, 15.	4.8	8
242	Heparin-Functionalized Adsorbents Eliminate Central Effectors of Immunothrombosis, including Platelet Factor 4, High-Mobility Group Box 1 Protein and Histones. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1823.	4.1	15
243	Thrombosis pathways in COVID-19 versus influenza-associated ARDS: a targeted proteomics approach. <i>Journal of Thrombosis and Haemostasis</i> , 2022, , .	3.8	4

#	ARTICLE	IF	CITATIONS
244	Effects of SARS-CoV-2 mRNA vaccines on platelet polyphosphate levels and inflammation: A pilot study. Biomedical Reports, 2022, 16, 21.	2.0	4
245	Emerging Role of Platelet-Endothelium Interactions in the Pathogenesis of Severe SARS-CoV-2 Infection-Associated Myocardial Injury. Frontiers in Immunology, 2022, 13, 776861.	4.8	12
246	Upregulation of cytokine signalling in platelets increases risk of thrombophilia in severe COVID-19 patients. Blood Cells, Molecules, and Diseases, 2022, 94, 102653.	1.4	10
247	Platelet Membrane: An Outstanding Factor in Cancer Metastasis. Membranes, 2022, 12, 182.	3.0	6
248	Platelets mediate inflammatory monocyte activation by SARS-CoV-2 spike protein. Journal of Clinical Investigation, 2022, 132, .	8.2	50
249	Platelet Phenotype Analysis of COVID-19 Patients Reveals Progressive Changes in the Activation of Integrin α IIb β 3, F13A1, the SARS-CoV-2 Target EIF4A1 and Annexin A5. Frontiers in Cardiovascular Medicine, 2021, 8, 779073.	2.4	21
250	Adverse Outcome in COVID-19 Is Associated With an Aggravating Hypo-Responsive Platelet Phenotype. Frontiers in Cardiovascular Medicine, 2021, 8, 795624.	2.4	23
251	Microfluidic post method for 3-dimensional modeling of platelet-leukocyte interactions. Analyst, The, 2022, 147, 1222-1235.	3.5	7
252	COVID-19 Induced Coagulopathy (CIC): Thrombotic Manifestations of Viral Infection. TH Open, 2022, 06, e70-e79.	1.4	4
253	Immune-Mediated Platelet Activation in COVID-19 and Vaccine-Induced Immune Thrombotic Thrombocytopenia. Frontiers in Immunology, 2022, 13, 837629.	4.8	14
254	Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells. Viruses, 2022, 14, 374.	3.3	12
255	The Composition and Physical Properties of Clots in COVID-19 Pathology. Diagnostics, 2022, 12, 580.	2.6	3
256	The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. Signal Transduction and Targeted Therapy, 2022, 7, 57.	17.1	34
257	Utility of the Specialized Pro-Resolving Mediators as Diagnostic and Prognostic Biomarkers in Disease. Biomolecules, 2022, 12, 353.	4.0	6
258	Cardiopulmonary Exercise Performance and Endothelial Function in Convalescent COVID-19 Patients. Journal of Clinical Medicine, 2022, 11, 1452.	2.4	18
259	A guide to molecular and functional investigations of platelets to bridge basic and clinical sciences. , 2022, 1, 223-237.		20
260	The COVID Complex: A Review of Platelet Activation and Immune Complexes in COVID-19. Frontiers in Immunology, 2022, 13, 807934.	4.8	24
261	Beyond Hemostasis: Platelet Innate Immune Interactions and Thromboinflammation. International Journal of Molecular Sciences, 2022, 23, 3868.	4.1	50

#	ARTICLE	IF	CITATIONS
262	Platelet olfactory receptor activation limits platelet reactivity and growth of aortic aneurysms. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	18
263	Cardiovascular disturbances in COVID-19: an updated review of the pathophysiology and clinical evidence of cardiovascular damage induced by SARS-CoV-2. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 93.	1.7	13
264	Association between COVID-19 Diagnosis and Coronary Artery Thrombosis: A Narrative Review. <i>Biomedicines</i> , 2022, 10, 702.	3.2	15
266	Platelets in Viral Infections “ Brave Soldiers or Trojan Horses. <i>Frontiers in Immunology</i> , 2022, 13, 856713.	4.8	14
267	TLT-1 Promotes Platelet“Monocyte Aggregate Formation to Induce IL-10“Producing B Cells in Tuberculosis. <i>Journal of Immunology</i> , 2022, 208, 1642-1651.	0.8	3
268	The Immune Response to SARS-CoV-2: Mechanisms, Aging, Sequelae, and Vaccines. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, 2166-2185.	2.4	3
269	Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3812.	4.1	17
271	Incidence of COVID-19-Associated Venous Thromboembolism Among Hospitalized Patients in McAllen, Texas, USA, in Late 2021. <i>Cureus</i> , 2022, 14, e23270.	0.5	0
272	How the Innate Immune System of the Blood Contributes to Systemic Pathology in COVID-19-Induced ARDS and Provides Potential Targets for Treatment. <i>Frontiers in Immunology</i> , 2022, 13, 840137.	4.8	11
273	Disease Severity in Moderate-to-Severe COVID-19 Is Associated With Platelet Hyperreactivity and Innate Immune Activation. <i>Frontiers in Immunology</i> , 2022, 13, 844701.	4.8	15
274	Intestinal Damage in COVID-19: SARS-CoV-2 Infection and Intestinal Thrombosis. <i>Frontiers in Microbiology</i> , 2022, 13, 860931.	3.5	15
275	Shining a light on platelet activation in COVID“19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, , .	3.8	3
276	Critical role of nitric oxide in impeding COVID-19 transmission and prevention: a promising possibility. <i>Environmental Science and Pollution Research</i> , 2022, 29, 38657-38672.	5.3	10
277	Platelet activation state in early stages of Covid-19. <i>Minerva Anestesiologica</i> , 2022, , .	1.0	2
278	Implication of Platelets in Immuno-Thrombosis and Thrombo-Inflammation. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 863846.	2.4	13
279	Aspirin use Reduces Platelet Hyperreactivity and Degranulation in COVID-19 Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, , .	2.7	3
280	Distinct Cellular Immune Responses to SARS-CoV-2 in Pregnant Women. <i>Journal of Immunology</i> , 2022, 208, 1857-1872.	0.8	16
281	Platelet-leukocyte crosstalk in COVID-19: How might the reciprocal links between thrombotic events and inflammatory state affect treatment strategies and disease prognosis?. <i>Thrombosis Research</i> , 2022, 213, 179-194.	1.7	17

#	ARTICLE	IF	CITATIONS
282	The endothelial glycocalyx in critical illness: A pediatric perspective. Matrix Biology Plus, 2022, 14, 100106.	3.5	9
283	Complement system component dysregulation is a distinctive feature of COVID-19 disease: a prospective and comparative analysis of patients admitted to the emergency department for suspected COVID-19 disease. Journal of Thrombosis and Thrombolysis, 2021, , 1.	2.1	6
284	COVID-19 and Venous Thromboembolism: From Pathological Mechanisms to Clinical Management. Journal of Personalized Medicine, 2021, 11, 1328.	2.5	6
285	The Pathobiological Basis for Thrombotic Complications in COVID-19: a Review of the Literature. Current Pathobiology Reports, 2021, 9, 107-117.	3.4	6
286	Fundamentals in Covid-19-Associated Thrombosis: Molecular and Cellular Aspects. Frontiers in Cardiovascular Medicine, 2021, 8, 785738.	2.4	20
287	Acute Mesenteric Ischemia in COVID-19 Patients. Journal of Clinical Medicine, 2022, 11, 200.	2.4	29
288	Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19. Journal of Clinical Medicine, 2021, 10, 5815.	2.4	6
289	Platelet Dysregulation in the Pathobiology of COVID-19. Hamostaseologie, 2021, , .	1.9	2
290	Editorial: special review series on viruses and platelets. Platelets, 2022, 33, 174-175.	2.3	0
291	COVID-19 and thrombosis: searching for evidence. Hematology American Society of Hematology Education Program, 2021, 2021, 621-627.	2.5	12
292	Venous Thrombosis and SARS-CoV-2. Hamostaseologie, 2022, 42, 240-247.	1.9	7
293	Post-COVID syndrome: prevalence, organ pathogenesis and routes of correction. A systematic review. Kuban Scientific Medical Bulletin, 2021, 28, 90-116.	0.4	4
294	Analysis of the Role of Female Hormones During Infection by COVID-19. Revista Brasileira De Ginecologia E Obstetricia, 2021, 43, 940-948.	0.8	3
295	Massive image-based single-cell profiling reveals high levels of circulating platelet aggregates in patients with COVID-19. Nature Communications, 2021, 12, 7135.	12.8	40
296	Hypercoagulation Detected by Rotational Thromboelastometry Predicts Mortality in COVID-19: A Risk Model Based on a Prospective Observational Study. TH Open, 2022, 06, e50-e59.	1.4	1
297	Prothrombotic Phenotype in COVID-19: Focus on Platelets. International Journal of Molecular Sciences, 2021, 22, 13638.	4.1	21
298	Increased Platelet-CD4+ T Cell Aggregates Are Correlated With HIV-1 Permissiveness and CD4+ T Cell Loss. Frontiers in Immunology, 2021, 12, 799124.	4.8	6
299	COVID-19 and immunothrombosis: Pathophysiology and therapeutic implications. Critical Reviews in Oncology/Hematology, 2021, 168, 103529.	4.4	22

#	ARTICLE	IF	CITATIONS
300	Binding of phosphatidylserineâ€‘positive microparticles by PBMCs classifies disease severity in COVIDâ€‘19 patients. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12173.	12.2	19
301	Implications of COVID-19 on Thrombotic Profile of Severely Affected Patients. <i>Pathobiology</i> , 2022, , 1-11.	3.8	0
302	Does mass management of chronic hepatitis C protect the Egyptian population against fulminant coronavirus disease-2019? â€‘Postulating a hypothesisâ€‘. <i>Egyptian Journal of Bronchology</i> , 2022, 16, .	0.8	2
303	An overview of post COVID sequelae. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2022, .	1.3	1
304	Platelet-monocyte interaction amplifies thromboinflammation through tissue factor signaling in COVID-19. <i>Blood Advances</i> , 2022, 6, 5085-5099.	5.2	32
305	Migrasomes: From Biogenesis, Release, Uptake, Rupture to Homeostasis and Diseases. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-13.	4.0	7
306	Periodontitis-Derived Dark-NETs in Severe Covid-19. <i>Frontiers in Immunology</i> , 2022, 13, 872695.	4.8	4
307	Platelet activation by SARS-CoV-2 implicates the release of active tissue factor by infected cells. <i>Blood Advances</i> , 2022, 6, 3593-3605.	5.2	37
308	Arenaviral infection causes bleeding in mice due to reduced serotonin release from platelets. <i>Science Signaling</i> , 2022, 15, eabb0384.	3.6	2
309	Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study. <i>Journal of Intensive Care Medicine</i> , 2022, 37, 1238-1249.	2.8	3
310	Signaling Through FcÎ³RIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 834988.	4.8	26
311	Neurovascular injury with complement activation and inflammation in COVID-19. <i>Brain</i> , 2022, 145, 2555-2568.	7.6	112
312	Plateletâ€‘leukocyte interactions in COVIDâ€‘19: Contributions to hypercoagulability, inflammation, and disease severity. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12709.	2.3	13
313	Assessment and Monitoring of Coagulation in Patients with COVID-19: A Review of Current Literature. <i>Hamostaseologie</i> , 2022, 42, 409-419.	1.9	3
314	Integrated analysis of transcriptomic data reveals the platelet response in COVID-19 disease. <i>Scientific Reports</i> , 2022, 12, 6851.	3.3	7
315	Weighted Gene Co-Expression Network Analysis to Identify Potential Biological Processes and Key Genes in COVID-19-Related Stroke. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-14.	4.0	9
316	Immuno-Thrombotic Complications of COVID-19: Implications for Timing of Surgery and Anticoagulation. <i>Frontiers in Surgery</i> , 2022, 9, .	1.4	23
317	Evidence showing lipotoxicity worsens outcomes in covid-19 patients and insights about the underlying mechanisms. <i>IScience</i> , 2022, 25, 104322.	4.1	12

#	ARTICLE	IF	CITATIONS
318	Sex differences in global metabolomic profiles of COVID-19 patients. <i>Cell Death and Disease</i> , 2022, 13, 461.	6.3	13
319	Identification of novel drug targets for the risk and prognosis of COVID-19. <i>Annals of Translational Medicine</i> , 2021, .	1.7	0
320	The phosphatase PTEN links platelets with immune regulatory functions of mouse T follicular helper cells. <i>Nature Communications</i> , 2022, 13, 2762.	12.8	7
321	Post-COVID-19 hematologic complications: a systematic review. <i>Expert Review of Hematology</i> , 2022, 15, 539-546.	2.2	6
322	Feasibility analysis and mechanism exploration of Rhei Radix et Rhizomea~Schisandrae Sphenantherae Fructus (RS) against COVID-19. <i>Journal of Medical Microbiology</i> , 2022, 71, .	1.8	11
324	Antiplatelet Activity of Riamilovir under Conditions of Lipopolysaccharide Intoxication. <i>Bulletin of Experimental Biology and Medicine</i> , 0, , .	0.8	1
325	Role of LL-37 in thrombotic complications in patients with COVID-19. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	5.4	13
326	The mechanistic basis linking cytokine storm to thrombosis in COVID-19. <i>Thrombosis Update</i> , 2022, 8, 100110.	0.9	2
327	Redox Mechanisms of Platelet Activation in Aging. <i>Antioxidants</i> , 2022, 11, 995.	5.1	4
328	Therapeutic Trends of Cerebrovascular Disease during the COVID-19 Pandemic and Future Perspectives. <i>Journal of Stroke</i> , 2022, 24, 179-188.	3.2	12
330	Cardiovascular Tropism and Sequelae of SARS-CoV-2 Infection. <i>Viruses</i> , 2022, 14, 1137.	3.3	6
331	Target and drug predictions for SARS-CoV-2 infection in hepatocellular carcinoma patients. <i>PLoS ONE</i> , 2022, 17, e0269249.	2.5	2
333	Pathophysiology of COVID-19: Critical Role of Hemostasis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, .	3.9	16
334	Cerebral venous sinus thrombosis in COVID 19 patients: report of 2 cases. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2022, , 101599.	0.3	0
335	Megakaryocytes and platelets embrace diversity in face of adversity. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1947-1950.	3.8	1
336	A review on the biological, epidemiological, and statistical relevance of COVID-19 paired with air pollution. <i>Environmental Advances</i> , 2022, 8, 100250.	4.8	12
338	Circulating tissue factorâ€positive extracellular vesicles and their association with thrombosis in different diseases. <i>Immunological Reviews</i> , 2022, 312, 61-75.	6.0	19
339	CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	55

#	ARTICLE	IF	CITATIONS
340	Cytokines and Lipid Mediators of Inflammation in Lungs of SARS-CoV-2 Infected Mice. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	10
341	Infection of lung megakaryocytes and platelets by SARS-CoV-2 anticipate fatal COVID-19. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	5.4	28
342	Platelets at the Crossroads of Pro-Inflammatory and Resolution Pathways during Inflammation. <i>Cells</i> , 2022, 11, 1957.	4.1	21
343	Preferential uptake of SARS-CoV-2 by pericytes potentiates vascular damage and permeability in an organoid model of the microvasculature. <i>Cardiovascular Research</i> , 2022, 118, 3085-3096.	3.8	17
344	Platelet Activation and Thrombosis in COVID-19. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 055-061.	2.7	17
345	Role of Endothelial Cells and Platelets in COVID-Related Cerebrovascular Events. <i>Stroke</i> , 2022, 53, 2389-2392.	2.0	2
347	Proteomic analysis of MSCa ⁺ -derived apoptotic vesicles identifies Fas inheritance to ameliorate haemophilia a via activating platelet functions. <i>Journal of Extracellular Vesicles</i> , 2022, 11, .	12.2	28
348	Acetylcholine, Fatty Acids, and Lipid Mediators Are Linked to COVID-19 Severity. <i>Journal of Immunology</i> , 2022, 209, 250-261.	0.8	17
349	Metabolite, protein, and tissue dysfunction associated with COVID-19 disease severity. <i>Scientific Reports</i> , 2022, 12, .	3.3	11
350	Platelet activation and partial desensitization are associated with viral xenophagy in patients with severe COVID-19. <i>Blood Advances</i> , 2022, 6, 3884-3898.	5.2	12
351	Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. <i>Journal of the Neurological Sciences</i> , 2022, 441, 120334.	0.6	2
352	Venous Thromboembolism in Sepsis: From Bench to Bedside. <i>Biomedicines</i> , 2022, 10, 1651.	3.2	5
353	Platelet proteome reveals features of cell death, antiviral response and viral replication in covid-19. <i>Cell Death Discovery</i> , 2022, 8, .	4.7	15
354	Thromboinflammation: From Atherosclerosis to COVID-19. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 1103-1112.	2.4	31
355	A method based on plateletpheresis to obtain functional platelet, ⁺ and ⁺ matched populations for research immunological studies. <i>Clinical and Experimental Allergy</i> , 2022, 52, 1157-1168.	2.9	5
356	Increased plasma level of soluble P-selectin in non-hospitalized COVID-19 convalescent donors. <i>Thrombosis Research</i> , 2022, 216, 120-124.	1.7	7
357	The interplay between inflammation and thrombosis in COVID-19: Mechanisms, therapeutic strategies, and challenges. <i>Thrombosis Update</i> , 2022, 8, 100117.	0.9	1
358	Dysregulated miRNAs network in the critical COVID-19: An important clue for uncontrolled immunothrombosis/thromboinflammation. <i>International Immunopharmacology</i> , 2022, 110, 109040.	3.8	4

#	ARTICLE	IF	CITATIONS
359	Proteomic Profile of Procoagulant Extracellular Vesicles Reflects Complement System Activation and Platelet Hyperreactivity of Patients with Severe COVID-19. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	3.9	9
360	Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2429-2438.	3.8	38
361	Is there an interplay between the <scp>SARSâ€CoV</scp>â€2 spike protein and <scp>Plateletâ€Activating</scp> factor?. <i>BioFactors</i> , 2022, 48, 1271-1283.	5.4	9
362	Activated Platelets and Platelet-Derived Extracellular Vesicles Mediate COVID-19-Associated Immunothrombosis. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	3.7	16
363	Intimal macrophages develop from circulating monocytes during vasculitis. <i>Clinical and Translational Immunology</i> , 2022, 11, .	3.8	1
364	Pharmacotherapy consideration of thrombolytic medications in COVID-19-associated ARDS. <i>Journal of Intensive Care</i> , 2022, 10, .	2.9	2
365	Thrombosis Mechanisms in Obese and Ischemic Stroke COVID-19 Patients: A Literature Review. , 2022, 2, 90-95.		0
366	Treatment of COVID-19 Pneumonia and Acute Respiratory Distress With Ramatroban, a Thromboxane A2 and Prostaglandin D2 Receptor Antagonist: A Four-Patient Case Series Report. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	8
367	Role of aging in Bloodâ€Brain Barrier dysfunction and susceptibility to SARS-CoV-2 infection: impacts on neurological symptoms of COVID-19. <i>Fluids and Barriers of the CNS</i> , 2022, 19, .	5.0	10
368	The role of platelets, neutrophils and endothelium in COVID-19 infection. <i>Expert Review of Hematology</i> , 2022, 15, 727-745.	2.2	7
369	Cardiac megakaryocytes in SARSâ€CoVâ€2 positive autopsies. <i>Histopathology</i> , 0, , .	2.9	0
370	S100A8/A9 drives the formation of procoagulant platelets through GPIbÎ±. <i>Blood</i> , 2022, 140, 2626-2643.	1.4	26
371	Bioinformatics analysis of potential pathogenesis and risk genes of immunoinflammation-promoted renal injury in severe COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
372	The Role of Extracellular Vesicles in COVID-19 Pathology. <i>Cells</i> , 2022, 11, 2496.	4.1	5
373	Peculiarities of hemostasis in patients with COVID-19. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 876-883.	0.8	0
374	Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients. <i>International Journal of Hematology</i> , 2022, 116, 937-946.	1.6	11
375	Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review. <i>Journal of Autoimmunity</i> , 2022, 132, 102898.	6.5	44
376	Understanding COVID-19-associated coagulopathy. <i>Nature Reviews Immunology</i> , 2022, 22, 639-649.	22.7	137

#	ARTICLE	IF	CITATIONS
377	COVID-19-specific transcriptomic signature detectable in blood across multiple cohorts. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	4
378	The Controversial Role of LPS in Platelet Activation In Vitro. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10900.	4.1	16
379	Pathophysiology of Coagulopathy in COVID-19. , 2022, , 223-234.		0
381	Redox stress in COVID-19: Implications for hematologic disorders. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101373.	1.7	0
382	Tissue factor in cancer-associated thromboembolism: possible mechanisms and clinical applications. <i>British Journal of Cancer</i> , 2022, 127, 2099-2107.	6.4	13
383	Relative Hypercoagulopathy of the SARS-CoV-2 Beta and Delta Variants when Compared to the Less Severe Omicron Variants Is Related to TEG Parameters, the Extent of Fibrin Amyloid Microclots, and the Severity of Clinical Illness. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 858-868.	2.7	26
384	Uncoupling of platelet granule release and integrin activation suggests GPIIb/IIIa as therapeutic target in COVID-19. <i>Blood Advances</i> , 0, , .	5.2	8
385	5-Methylcytosine (m5C) modification in peripheral blood immune cells is a novel non-invasive biomarker for colorectal cancer diagnosis. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	8
386	In silico investigation of Panax ginseng lead compounds against COVID-19 associated platelet activation and thromboembolism. <i>Journal of Ginseng Research</i> , 2023, 47, 283-290.	5.7	3
387	Gut Microbiota Dynamics in Relation to Long-COVID-19 Syndrome: Role of Probiotics to Combat Psychiatric Complications. <i>Metabolites</i> , 2022, 12, 912.	2.9	10
388	The impact of platelets on pulmonary microcirculation throughout COVID-19 and its persistent activating factors. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
389	Increased platelet activation and platelet-inflammasome engagement during chikungunya infection. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3
390	Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	10
391	Host cell membrane proteins located near SARS-CoV-2 spike protein attachment sites are identified using proximity labeling and proteomic analysis. <i>Journal of Biological Chemistry</i> , 2022, 298, 102500.	3.4	4
392	Tissue Factor and COVID-19: An Update. <i>Current Drug Targets</i> , 2022, 23, 1573-1577.	2.1	6
393	Influenza A virus infection instructs hematopoiesis to megakaryocyte-lineage output. <i>Cell Reports</i> , 2022, 41, 111447.	6.4	5
394	Coronavirus disease 2019 (<sc>COVID</sc>â€19): Focus on peripheral blood cell morphology. <i>British Journal of Haematology</i> , 2023, 200, 404-419.	2.5	6
395	Tissue factor in COVID-19-associated coagulopathy. <i>Thrombosis Research</i> , 2022, 220, 35-47.	1.7	16

#	ARTICLE	IF	CITATION
396	Zoster-Associated Prothrombotic Plasma Exosomes and Increased Stroke Risk. Journal of Infectious Diseases, 2023, 227, 993-1001.	4.0	3
397	Severe COVID-19 patients display hyper-activated NK cells and NK cell-platelet aggregates. Frontiers in Immunology, 0, 13, .	4.8	13
398	In-hospital Mortality Rates in SARS-CoV-2 Patients Treated with Enoxaparin and Heparin. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962211318.	1.7	1
399	Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options. Life, 2022, 12, 1605.	2.4	12
400	Persisting Platelet Activation and Hyperactivity in COVID-19 Survivors. Circulation Research, 2022, 131, 944-947.	4.5	22
402	Coenzyme Q10 Attenuates Human Platelet Aggregation Induced by SARS-CoV-2 Spike Protein via Reducing Oxidative Stress In Vitro. International Journal of Molecular Sciences, 2022, 23, 12345.	4.1	3
403	Hyperresponsive Platelets and a Reduced Platelet Granule Release Capacity Are Associated with Severity and Mortality in COVID-19 Patients. Thrombosis and Haemostasis, 2022, 122, 2001-2010.	3.4	7
404	Inflammatory and Hemostatic Markers in COVID-19 Patients with Arterial Thrombosis Are Significantly Lower at Hospital Admission than in COVID-19 Patients without Thrombosis. Viruses, 2022, 14, 2330.	3.3	0
405	Are platelet volume indices of clinical use in COVID-19? A systematic review. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	7
407	COVID-19 and antiphospholipid antibodies. Best Practice and Research in Clinical Haematology, 2022, 35, 101402.	1.7	12
408	Thrombopoietin participates in platelet activation in COVID-19 patients. EBioMedicine, 2022, 85, 104305.	6.1	3
409	ĐŸĐĐĐ”Đ•ĐœĐ†Đ~ COVID-19 ĐœĐĐ”Đ’ĐĐ•Đ†Đ†ĐœĐ® ĐŁ Đ”Đ’Đ•ĐĐžĐšĐ”: ĐŸĐĐžĐ’Đ•Đ•ĐœĐĐ† ĐŸĐ”ĐœĐĐĐĐ~ ĐŸĐ•Đ”Đ†ĐĐœĐĐ†		
410	Platelet-leukocyte interactions: immunoregulatory role and pathophysiological relevance. Medical Immunology (Russia), 2022, 24, 871-888.	0.4	0
411	Platelet in thrombo-inflammation: Unraveling new therapeutic targets. Frontiers in Immunology, 0, 13, .	4.8	21
412	Clinical assessment of endothelial function in convalescent COVID-19 patients: a meta-analysis with meta-regressions. Annals of Medicine, 2022, 54, 3233-3248.	3.8	16
413	Pathophysiological mechanisms of thrombosis in acute and long COVID-19. Frontiers in Immunology, 0, 13, .	4.8	24
415	Early antithrombotic therapy for another highly lethal viral pneumonia pandemic. Clinical Microbiology and Infection, 2023, 29, 284-287.	6.0	1
416	Inflammation in COVID-19: A Risk for Superinfections. Covid, 2022, 2, 1609-1624.	1.5	4

#	ARTICLE	IF	CITATIONS
417	The use of acetylsalicylic acid for prevention of cardiovascular complications in patients undergoing COVID-19. A review of current recommendations. <i>Kardiologiya I Serdechno-Sosudistaya Khirurgiya</i> , 2022, 15, 656.	0.3	0
418	Platelet caspase-1 and Bruton tyrosine kinase activation in patients with COVID-19 is associated with disease severity and reversed in vitro by ibrutinib. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12811.	2.3	2
419	Correlation between COVID-19 and hepatitis B: A systematic review. <i>World Journal of Gastroenterology</i> , 0, 28, 6599-6618.	3.3	8
420	Transcriptional reprogramming from innate immune functions to a pro-thrombotic signature by monocytes in COVID-19. <i>Nature Communications</i> , 2022, 13, .	12.8	17
422	Molecular Pathogenesis of Fibrosis, Thrombosis and Surfactant Dysfunction in the Lungs of Severe COVID-19 Patients. <i>Biomolecules</i> , 2022, 12, 1845.	4.0	5
423	Bioinformatics insights into the genes and pathways on severe COVID-19 pathology in patients with comorbidities. <i>Frontiers in Physiology</i> , 0, 13, .	2.8	2
424	Deciphering the role of platelets in severe allergy by an integrative omics approach. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2023, 78, 1319-1332.	5.7	4
425	Potential therapeutic value of necroptosis inhibitor for the treatment of COVID-19. <i>European Journal of Medical Research</i> , 2022, 27, .	2.2	5
426	Platelets in COVID-19 disease: friend, foe, or both?. <i>Pharmacological Reports</i> , 2022, 74, 1182-1197.	3.3	2
427	Flavonoids as a therapeutical option for the treatment of thrombotic complications associated with COVID-19. <i>Phytotherapy Research</i> , 2023, 37, 1092-1114.	5.8	6
428	Molecular signatures in the progression of COVID-19 severity. <i>Scientific Reports</i> , 2022, 12, .	3.3	4
429	Serum interleukin 1 β and sP-selectin as biomarkers of inflammation and thrombosis, could they be predictors of disease severity in COVID 19 Egyptian patients? (a cross-sectional study). <i>Thrombosis Journal</i> , 2022, 20, .	2.1	3
430	Platelet Reactivity and Inflammatory Phenotype Induced by Full-Length Spike SARS-CoV-2 Protein and Its RBD Domain. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15191.	4.1	1
431	Antiplatelet Drugs in COVID-19: Mechanism of Action and Effect on Prognosis. <i>Contemporary Cardiology</i> , 2022, , 331-349.	0.1	0
432	Platelet-Neutrophil Crosstalk in Thrombosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1266.	4.1	7
433	Pathogenesis and Mechanisms of SARS-CoV-2 Infection in the Intestine, Liver, and Pancreas. <i>Cells</i> , 2023, 12, 262.	4.1	13
434	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities. <i>PLoS Pathogens</i> , 2023, 19, e1011063.	4.7	7
435	Coagulation Disorders in Sepsis and COVID-19—Two Sides of the Same Coin? A Review of Inflammation-“Coagulation Crosstalk in Bacterial Sepsis and COVID-19. <i>Journal of Clinical Medicine</i> , 2023, 12, 601.	2.4	8

#	ARTICLE	IF	CITATIONS
436	P2Y12 Inhibition Suppresses Proinflammatory Platelet-Monocyte Interactions. <i>Thrombosis and Haemostasis</i> , 2023, 123, 231-244.	3.4	7
437	From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era. <i>Biomedicine and Pharmacotherapy</i> , 2023, 158, 114208.	5.6	9
438	Bystander effect of SARS-CoV-2 spike protein on human monocytic THP-1 cell activation and initiation of prothrombotic stimulus representing severe COVID-19. <i>Journal of Inflammation</i> , 2022, 19, .	3.4	4
439	The Implications of COVID-19 Infection on Hematologic Parameters and Coagulation Activity: A Review. <i>Biomedical and Pharmacology Journal</i> , 2022, 15, 1837-1851.	0.5	1
440	Animal models and SARS-CoV-2-induced pulmonary and neurological injuries. <i>Memorias Do Instituto Oswaldo Cruz</i> , 0, 117, .	1.6	0
442	Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin. <i>Biomedicines</i> , 2023, 11, 338.	3.2	3
443	SARS-CoV-2 Possible Etiology of Cerebral Venous Thrombosis in a Teenager: Case Report and Review of Literature. <i>Viruses</i> , 2023, 15, 405.	3.3	4
444	An Overview of Fluvoxamine and its Use in SARS-CoV-2 Treatment. <i>Cureus</i> , 2023, , .	0.5	0
445	Dysregulated platelet function in COVID-19 patients. <i>Obstetrics, Gynecology and Reproduction</i> , 2023, 16, 692-705.	0.5	2
446	Nephrological complications in patients after COVID-19 infection. <i>Quality in Sport</i> , 2023, 9, 29-34.	0.1	0
447	High mobility group box 1, <scp>ATP</scp>, lipid mediators, and tissue factor are elevated in <scp>COVID</scp>-19 patients: <scp>HMGB1</scp> as a biomarker of worst prognosis. <i>Clinical and Translational Science</i> , 2023, 16, 631-646.	3.1	7
448	A Study on the Impact of Diabetes Mellitus on the Severity of COVID-19-Associated Mucormycosis. <i>Annals of the National Academy of Medical Sciences (India)</i> , 2023, 59, 027-035.	0.3	0
449	Coagulopathy is Initiated with Endothelial Dysfunction and Disrupted Fibrinolysis in Patients with COVID-19 Disease. <i>Indian Journal of Clinical Biochemistry</i> , 2023, 38, 220-230.	1.9	2
450	Increased Platelet Activation demonstrated by Elevated CD36 and P-Selectin Expression in 1-Year Post-Recovered COVID-19 Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 561-564.	2.7	6
451	Risk of Thrombosis during and after a SARS-CoV-2 Infection: Pathogenesis, Diagnostic Approach, and Management. <i>Hematology Reports</i> , 2023, 15, 225-243.	0.8	5
452	Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies. <i>Thrombosis Research</i> , 2023, 225, 47-56.	1.7	2
453	Immunothrombosis biomarkers as potential predictive factors of acute respiratory distress syndrome in moderate-to-critical COVID-19: A single-center, retrospective cohort study. <i>Immunology Letters</i> , 2023, 254, 30-38.	2.5	1
454	Peripheral blood mononuclear cell tissue factor (F3 gene) transcript levels and circulating extracellular vesicles are elevated in severe coronavirus 2019 (COVID-19) disease. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 629-638.	3.8	8

#	ARTICLE	IF	CITATIONS
455	Early SARS-CoV-2 infection: Platelet-neutrophil complexes and platelet function. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100025.	2.3	4
456	Alterations in platelet proteome signature and impaired platelet integrin $\alpha\text{IIb}\beta_3$ activation in patients with COVID-19. Journal of Thrombosis and Haemostasis, 2023, 21, 1307-1321.	3.8	6
457	Platelet activation and coronavirus disease 2019 mortality: Insights from coagulopathy, antiplatelet therapy and inflammation. Archives of Cardiovascular Diseases, 2023, 116, 183-191.	1.6	4
459	Platelet-instructed SPP1+ macrophages drive myofibroblast activation in fibrosis in a CXCL4-dependent manner. Cell Reports, 2023, 42, 112131.	6.4	38
460	Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases. Life Sciences, 2023, 319, 121531.	4.3	15
461	Activated Platelets Mediate Monocyte Killing of Klebsiella pneumoniae. Infection and Immunity, 2023, 91, .	2.2	5
462	SARS-CoV-2 Lysate Stimulation Impairs the Release of Platelet-like Particles and Megakaryopoiesis in the MEG-01 Cell Line. International Journal of Molecular Sciences, 2023, 24, 4723.	4.1	0
463	An Emerging Role for Type I Interferons as Critical Regulators of Blood Coagulation. Cells, 2023, 12, 778.	4.1	6
464	Incidence and clinical outcomes of bacterial superinfections in critically ill patients with COVID-19. Frontiers in Medicine, 0, 10, .	2.6	6
465	4-Hydroxynonenal Is Linked to Sleep and Cognitive Disturbances in Children: Once upon the Time of COVID-19. , 0, , .		0
466	Prognostic value of cellular population data in patients with COVID-19. Informatics in Medicine Unlocked, 2023, 38, 101207.	3.4	2
467	<scp>COVID</scp>â€19 infectionâ€associated platelet and neutrophil activation is blunted by previous antiâ€<scp>SARSâ€C</scp>o<scp>V</scp>â€2 vaccination. British Journal of Haematology, 2023, 201, 851-856.	2.5	5
468	Increased platelet activation and lower platelet-monocyte aggregates in COVID-19 patients with severe pneumonia. PLoS ONE, 2023, 18, e0282785.	2.5	3
469	Platelet, a key regulator of innate and adaptive immunity. Frontiers in Medicine, 0, 10, .	2.6	3
470	Infection with SARS-CoV-2 Is Associated with Elevated Levels of IP-10, MCP-1, and IL-13 in Sepsis Patients. Diagnostics, 2023, 13, 1069.	2.6	1
471	Retrospective Study of Thrombosis in Hospitalized Patients with COVID-19 in Rural North Carolina. North Carolina Medical Journal, 2023, 84, .	0.2	0
472	Advanced Therapies for Patients with COVID-19. , 2023, , 77-92.		0
473	Tissue factor activity of small and large extracellular vesicles in different diseases. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100124.	2.3	2

#	ARTICLE	IF	CITATIONS
474	Circulating SARS-CoV-2+ megakaryocytes are associated with severe viral infection in COVID-19. Blood Advances, 2023, 7, 4200-4214.	5.2	7
475	Effects of the circulating environment of COVID-19 on platelet and neutrophil behavior. Frontiers in Immunology, 0, 14, .	4.8	0
476	Intestinal barrier dysfunction as a key driver of severe COVID-19. World Journal of Virology, 0, 12, 68-90.	2.9	4
480	SARS-CoV-2 RBD and Its Variants Can Induce Platelet Activation and Clearance: Implications for Antibody Therapy and Vaccinations against COVID-19. Research, 2023, 6, .	5.7	3
481	Neutrophil Extracellular Traps and Platelet Activation for Identifying Severe Episodes and Clinical Trajectories in COVID-19. International Journal of Molecular Sciences, 2023, 24, 6690.	4.1	2
482	Platelets and platelet-derived vesicles as an innovative cellular and subcellular platform for managing multiple sclerosis. Molecular Biology Reports, 2023, 50, 4675-4686.	2.3	3
483	Acute to post-acute COVID-19 thromboinflammation persistence: Mechanisms and potential consequences. Current Research in Immunology, 2023, 4, 100058.	2.8	9
484	Nematic Fibrin Fibers Enabling Vascularized Thrombus Implants Facilitate Scarless Cutaneous Wound Healing. Advanced Materials, 2023, 35, .	21.0	7
485	Molecular and genetic aspects of the pathogenesis of COVID-associated thrombosis. Reports of Vinnytsia National Medical University, 2023, 27, 166-173.	0.1	0
486	Status of major hemostatic components in the setting of COVID-19: the effect on endothelium, platelets, coagulation factors, fibrinolytic system, and complement. Annals of Hematology, 2023, 102, 1307-1322.	1.8	7
487	Serum lipid mediator profiles in COVID-19 patients and lung disease severity: a pilot study. Scientific Reports, 2023, 13, .	3.3	4
489	Serum from Men with the Severe Form of COVID-19 Impairs the Nitric Oxide Signaling Pathway in Isolated Corpus Cavernosum from Mice: An In Vitro Study. Andrologia, 2023, 2023, 1-13.	2.1	0
490	Variant-derived SARS-CoV-2 spike protein does not directly cause platelet activation or hypercoagulability. Clinical and Experimental Medicine, 2023, 23, 3701-3708.	3.6	3
491	Alterations in the megakaryocyte transcriptome impacts platelet function in sepsis and COVID-19 infection. Thrombosis Research, 2023, , .	1.7	0
492	To Study the Correlation of Clinical Severity and Cytokine Storm in COVID-19 Pulmonary Embolism Patients by Using Computed Tomography Pulmonary Angiography (CTPA) Qanadli Clot Burden Scoring System. Cureus, 2023, , .	0.5	0
493	The efficacy of therapeutic plasma exchange in COVID-19 patients on endothelial tightness in vitro is hindered by platelet activation. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
494	Platelets and SARS-CoV-2 During COVID-19: Immunity, Thrombosis, and Beyond. Circulation Research, 2023, 132, 1272-1289.	4.5	13
495	Multi-omics blood atlas reveals unique features of immune and platelet responses to SARS-CoV-2 Omicron breakthrough infection. Immunity, 2023, 56, 1410-1428.e8.	14.3	11

#	ARTICLE	IF	CITATIONS
496	Platelet-neutrophil interaction in COVID-19 and vaccine-induced thrombotic thrombocytopenia. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	5
497	Impact of P-selectinâ€“PSGL-1 Axis on Platelet-Endothelium-Leukocyte Interactions in Fatal COVID-19. <i>Laboratory Investigation</i> , 2023, 103, 100179.	3.7	2
498	Effect of P2Y12 Inhibitors on Organ Supportâ€“Free Survival in Critically Ill Patients Hospitalized for COVID-19. <i>JAMA Network Open</i> , 2023, 6, e2314428.	5.9	4
499	Proteomic analysis of circulating immune cells identifies cellular phenotypes associated with COVID-19 severity. <i>Cell Reports</i> , 2023, 42, 112613.	6.4	2
500	NLRP3 inflammasome and interleukin-1 contributions to COVID-19-associated coagulopathy and immunothrombosis. <i>Cardiovascular Research</i> , 2023, 119, 2046-2060.	3.8	8
501	Platelets exacerbate cardiovascular inflammation in a murine model of Kawasaki disease vasculitis. <i>JCI Insight</i> , 2023, 8, .	5.0	5
502	Sepsis â€“ it is all about the platelets. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	5
503	New Insights into Immunopathology Associated to Bothrops lanceolatus Snake Envenomation: Focus on PLA2 Toxin. <i>International Journal of Molecular Sciences</i> , 2023, 24, 9931.	4.1	1
504	Dimethyl fumarate and 4-octyl itaconate are anticoagulants that suppress Tissue Factor in macrophages via inhibition of Type I Interferon. <i>Nature Communications</i> , 2023, 14, .	12.8	11
505	Editorial: COVID-19 and thrombo-inflammatory responses. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	0
506	Shedding Light on the Cell Biology of Platelet-Derived Extracellular Vesicles and Their Biomedical Applications. <i>Life</i> , 2023, 13, 1403.	2.4	3
507	Effects of Recombinant SARS-CoV-2 Spike Protein Variants on Platelet Morphology and Activation. <i>Seminars in Thrombosis and Hemostasis</i> , 2024, 50, 275-283.	2.7	2
508	COVID-19 and non-steroid anti-inflammatory drugs. <i>Emergency Medicine</i> , 2023, 19, 134-140.	0.2	0
509	Circulating cellular clusters are associated with thrombotic complications and clinical outcomes in COVID-19. <i>IScience</i> , 2023, 26, 107202.	4.1	3
510	Thrombotic Mechanism Involving Platelet Activation, Hypercoagulability and Hypofibrinolysis in Coronavirus Disease 2019. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7975.	4.1	7
511	Clinical course and diagnosis of cerebral vein and sinus thrombosis associated with COVID-19 in young and middle-aged patients. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2023, 15, 34-40.	1.2	0
512	Effect of Vaccination on Platelet Mitochondrial Bioenergy Function of Patients with Post-Acute COVID-19. <i>Viruses</i> , 2023, 15, 1085.	3.3	0
513	Monocyte Tissue Factor Expression: Lipopolysaccharide Induction and Roles in Pathological Activation of Coagulation. <i>Thrombosis and Haemostasis</i> , 2023, 123, 1017-1033.	3.4	6

#	ARTICLE	IF	CITATIONS
514	Platelet-monocyte aggregates: molecular mediators of thromboinflammation. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	3
516	Monitoring the Coagulation Profile of COVID-19 Patients Using Standard and ClotPro® Hemostasis Tests. <i>Medicina (Lithuania)</i> , 2023, 59, 1202.	2.0	0
517	Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients with COVID-19: An Open-label, Randomized Clinical Trial. <i>Indian Journal of Critical Care Medicine</i> , 2023, 27, 517-521.	0.9	0
518	Immunothrombosis and its underlying biological mechanisms. <i>Hematology, Transfusion and Cell Therapy</i> , 2024, 46, 49-57.	0.2	1
519	Exploring dysregulated immune response genes and endothelial dysfunction biomarkers as predictors of severe COVID-19. <i>International Immunopharmacology</i> , 2023, 122, 110610.	3.8	0
520	Hyper-coagulopathy state in COVID-19: a pivotal challenge. <i>Current Respiratory Medicine Reviews</i> , 2023, 19, .	0.2	0
521	Treatment of COVID-19-Induced Systematic Inflammatory Response and Multiple Organ Failure Using Xuebijing. , 2023, 10, .		0
523	Binding of respiratory syncytial virus particles to platelets does not result in their degranulation in vitro. <i>Access Microbiology</i> , 2023, 5, .	0.5	0
524	Bone marrow alterations in COVID-19 infection: The root of hematological problems. <i>Current Research in Translational Medicine</i> , 2023, 71, 103407.	1.8	0
525	Phospholipase A2 as a therapeutic target for treating COVID-19. , 2023, , 343-351.		0
526	Impairment of platelet function in both mild and severe <scp>COVID</scp>â€“19 patients. <i>British Journal of Haematology</i> , 2023, 203, 656-667.	2.5	0
527	Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)â€”Insights from Clinical Cases, In Vitro Studies and Murine Models. <i>Journal of Clinical Medicine</i> , 2023, 12, 6126.	2.4	0
528	Platelet mitochondria, a potent immune mediator in neurological diseases. <i>Frontiers in Physiology</i> , 0, 14, .	2.8	0
529	Severe fever with thrombocytopenia syndrome virus induces platelet activation and apoptosis via a reactive oxygen species-dependent pathway. <i>Redox Biology</i> , 2023, 65, 102837.	9.0	1
530	Differential platelet activation through an interaction with spike proteins of different SARS-CoV-2 variants. <i>Journal of Thrombosis and Thrombolysis</i> , 2023, 56, 538-547.	2.1	2
531	SARS-CoV-2 Omicron variant infection affects blood platelets, a comparative analysis with Delta variant. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
532	Leishmania major-derived lipophosphoglycan influences the hostâ€™s early immune response by inducing platelet activation and DKK1 production via TLR1/2. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
533	Prolonged platelet hyperactivity after <scp>COVID</scp>â€“19 infection. <i>British Journal of Haematology</i> , 2024, 204, 492-496.	2.5	1

#	ARTICLE	IF	CITATIONS
534	CD40L Activates Platelet Integrin $\alpha\text{IIb}\beta_3$ by Binding to the Allosteric Site (Site 2) in a KGD-Independent Manner and HIGM1 Mutations Are Clustered in the Integrin-Binding Sites of CD40L. <i>Cells</i> , 2023, 12, 1977.	4.1	1
535	Flow Cytometry Analysis of IL-1 Receptors and Toll-Like Receptors on Platelets and Platelet-Derived Extracellular Vesicles. <i>Methods in Molecular Biology</i> , 2023, , 117-137.	0.9	0
536	Hyperactivity of platelets and increased megakaryopoiesis in COVID-19 patients with acute respiratory distress syndrome. , 2023, 1, .		0
537	Platelets of COVID-19 patients display mitochondrial dysfunction, oxidative stress, and energy metabolism failure compatible with cell death. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 102213.	2.3	0
538	Single-cell multi-omics analysis of COVID-19 patients with pre-existing autoimmune diseases shows aberrant immune responses to infection. <i>European Journal of Immunology</i> , 2024, 54, .	2.9	1
539	Diagnosis and treatment of coagulopathy using thromboelastography with platelet mapping is associated with decreased risk of pulmonary failure in COVID-19 patients. <i>Blood Coagulation and Fibrinolysis</i> , 0, , .	1.0	0
540	Glycolytic reprogramming fuels myeloid cell-driven hypercoagulability. <i>Journal of Thrombosis and Haemostasis</i> , 2024, 22, 394-409.	3.8	0
541	Changes in the Human Blood System in Patients with COVID-19. <i>Russian Archives of Internal Medicine</i> , 2023, 13, 335-343.	0.2	0
542	Post-COVID-19 thrombotic sequelae: The potential role of persistent platelet hyperactivity. <i>British Journal of Haematology</i> , 2024, 204, 383-385.	2.5	0
543	Enoxaparin improves COVID-19 by reducing Neutrophils Extracellular Traps (NETs) production. <i>Clinical Immunology</i> , 2023, 257, 109836.	3.2	1
544	Platelet aggregates detected using quantitative phase imaging associate with COVID-19 severity. <i>Communications Medicine</i> , 2023, 3, .	4.2	0
545	COVID-19 and the Concept of Thrombo-Inflammation: Review of the Relationship between Immune Response, Endothelium and Coagulation. <i>Journal of Clinical Medicine</i> , 2023, 12, 7245.	2.4	2
546	Presence of procoagulant peripheral blood mononuclear cells in severe COVID-19 patients relate to ventilation perfusion mismatch and precede pulmonary embolism. <i>Journal of Critical Care</i> , 2024, 79, 154463.	2.2	1
547	Megakaryocytes possess a STING pathway that is transferred to platelets to potentiate activation. <i>Life Science Alliance</i> , 2024, 7, e202302211.	2.8	1
548	Expression of Tissue Factor and Platelet/Leukocyte Markers on Extracellular Vesicles Reflect Platelet-Leukocyte Interaction in Severe COVID-19. <i>International Journal of Molecular Sciences</i> , 2023, 24, 16886.	4.1	1
549	Platelet Activation and Mechanisms of Thromboembolism Formation in Patients with Severe COVID-19. Alternative Mechanisms of Hemostasis System Activity. <i>Biology Bulletin Reviews</i> , 2023, 13, 599-621.	0.9	0
550	Long-term hypercoagulability, endotheliopathy and inflammation following acute SARS-CoV-2 infection. <i>Expert Review of Hematology</i> , 2023, 16, 1035-1048.	2.2	3
551	The Potential Role of Nitric Oxide as a Therapeutic Agent against SARS-CoV-2 Infection. <i>International Journal of Molecular Sciences</i> , 2023, 24, 17162.	4.1	0

#	ARTICLE	IF	CITATIONS
552	The Ways of the Virus: Interactions of Platelets and Red Blood Cells with SARS-CoV-2, and Their Potential Pathophysiological Significance in COVID-19. International Journal of Molecular Sciences, 2023, 24, 17291.	4.1	0
553	The Role of Platelet Molecules in Risk Stratification of Patients with COVID-19. Hemato, 2023, 4, 364-383.	0.6	1
554	Direct and indirect effects of Puumala hantavirus on platelet function. Thrombosis Research, 2024, 233, 41-54.	1.7	1
556	Signaling network analysis reveals fostamatinib as a potential drug to control platelet hyperactivation during SARS-CoV-2 infection. Frontiers in Immunology, 0, 14, .	4.8	0
557	Construction and study of blood purification membrane modified with PDE inhibitor: Investigation of antiplatelet activity and hemocompatibility. Colloids and Surfaces B: Biointerfaces, 2024, 234, 113725.	5.0	0
558	SARS-CoV-2 primed plateletsâ€™derived microRNAs enhance NETs formation by extracellular vesicle transmission and TLR7/8 activation. Cell Communication and Signaling, 2023, 21, .	6.5	3
559	Distinct targeting and uptake of platelet and red blood cellâ€™derived extracellular vesicles into immune cells. , 2024, 3, .		0
560	Reduced monocyte proportions and responsiveness in convalescent COVID-19 patients. Frontiers in Immunology, 0, 14, .	4.8	0
561	COVID-19 pathogenesis. Progress in Molecular Biology and Translational Science, 2024, , .	1.7	0
562	Platelets in Hemostasis, Thrombosis, and Inflammation After Major Trauma. Arteriosclerosis, Thrombosis, and Vascular Biology, 2024, 44, 545-557.	2.4	0
564	An early warning indicator of mortality risk in patients with COVID-19: the neutrophil extracellular traps/neutrophilic segmented granulocyte ratio. Frontiers in Immunology, 0, 15, .	4.8	0
565	Coagulation and Inflammation in COVID-19: Reciprocal Relationship between Inflammatory and Coagulation Markers. Annals of Hematology, 0, , .	1.8	0
566	Impact of production methods and storage conditions on extracellular vesicles in packed red blood cells and platelet concentrates. Transfusion and Apheresis Science, 2024, 63, 103891.	1.0	0
567	Pharmacogenetics and Pharmacogenomics Impact on Aspirin Response. , 0, , .		0
568	Causal Effects of COVID-19 on the Risk of Thrombosis: A Two-Sample Mendel Randomization Study. Thrombosis and Haemostasis, 0, , .	3.4	0
569	Proteomics of serum-derived extracellular vesicles are associated with the severity and different clinical profiles of patients with COVID-19: An exploratory secondary analysis. Cytotherapy, 2024, 26, 444-455.	0.7	0
570	COVID-19-Induced Vascular Coagulopathy. , 2023, , .		0
571	Tissue Factor and COVID-19 Associated Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2024, 44, 523-529.	2.4	0

#	ARTICLE	IF	CITATIONS
572	Phenotype prediction from single-cell RNA-seq data using attention-based neural networks. Bioinformatics, 2024, 40, .	4.1	0
573	Association of PADI2 and PADI4 polymorphisms in COVID-19 host severity and non-survival. Heliyon, 2024, 10, e27997.	3.2	0
574	The fluorochrome-to-protein ratio is crucial for the flow cytometric detection of tissue factor on extracellular vesicles. Scientific Reports, 2024, 14, .	3.3	0
575	Clinical significance of platelet mononuclear cell aggregates in patients with sepsis and acute respiratory distress syndrome. World Journal of Clinical Cases, 0, 12, 966-972.	0.8	0
576	Laboratory Puzzle of Oxidative Stress, Parameters of Hemostasis and Inflammation in Hospitalized Patients with COVID-19. Biomedicines, 2024, 12, 636.	3.2	0